Protalix Cash from 2010 to 2026

PLX Stock

USD 2.07 0.02 0.98%

Protalix Biotherapeutics Cash yearly trend continues to be fairly stable with very little volatility. Cash is likely to outpace its year average in 2026. Cash is the total amount of money in the form of currency that Protalix Biotherapeutics has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals

Cash

First Reported

1997-03-31

Previous Quarter

17.9 M

Current Value

13.6 M

Quarterly Volatility

24.1 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Protalix Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protalix Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.2 M, Selling General Administrative of 49.3 M or Other Operating Expenses of 32.3 M, as well as many indicators such as Price To Sales Ratio of 2.79, Dividend Yield of 0.0 or PTB Ratio of 3.45. Protalix financial statements analysis is a perfect complement when working with Protalix Biotherapeutics Valuation or Volatility modules.

Build AI portfolio with Protalix Stock

Check out the analysis of Protalix Biotherapeutics Correlation against competitors.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

Latest Protalix Biotherapeutics' Cash Growth Pattern

Below is the plot of the Cash of Protalix Biotherapeutics over the last few years. Cash refers to the most liquid asset of Protalix Biotherapeutics, which is listed under current asset account on Protalix Biotherapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Protalix Biotherapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Protalix Biotherapeutics account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Protalix Biotherapeutics' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protalix Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.

Cash

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Cash

Timeline

Protalix Cash Regression Statistics

	Arithmetic Mean	37,604,448
	Geometric Mean	27,750,016
	Coefficient Of Variation	61.87
	Mean Deviation	18,820,637
	Median	31,413,659
	Standard Deviation	23,266,505
	Sample Variance	541.3T
	Range	85.6M
	R-Value	(0.36)
	Mean Square Error	502.2T
	R-Squared	0.13
	Significance	0.15
	Slope	(1,662,758)
	Total Sum of Squares	8661.3T

Protalix Cash History

	2026	31.4 M
	2025	22.7 M
	2024	19.8 M
	2023	23.6 M
	2022	17.1 M
	2021	39 M
	2020	18.3 M

Other Fundumenentals of Protalix Biotherapeutics

	Cash And Short Term Investments
	Cash And Equivalents
	Change In Cash
	Free Cash Flow

Protalix Biotherapeutics Cash component correlations

	Cash And Equivalents	Change In Cash	Free Cash Flow	Begin Period Cash Flow	End Period Cash Flow	Free Cash Flow Yield	Free Cash Flow Per Share	Cash Per Share	Ev To Free Cash Flow	Cash Ratio	Cash Conversion Cycle	Price Cash Flow Ratio	Cash Flow To Debt Ratio
Cash And Equivalents		0.26	-0.37	0.44	0.63	0.32	0.07	0.41	-0.28	0.57	-0.41	-0.22	-0.34
Change In Cash	0.26		0.12	-0.36	0.42	0.26	0.33	0.23	-0.06	0.31	0.11	0.02	-0.03
Free Cash Flow	-0.37	0.12		-0.59	-0.47	0.38	0.52	0.29	-0.23	0.02	0.29	-0.18	-0.07
Begin Period Cash Flow	0.44	-0.36	-0.59		0.69	0.02	-0.22	-0.14	0.44	-0.12	-0.04	0.4	0.36
End Period Cash Flow	0.63	0.42	-0.47	0.69		0.23	0.05	0.03	0.38	0.12	0.05	0.41	0.33
Free Cash Flow Yield	0.32	0.26	0.38	0.02	0.23		0.77	0.04	-0.18	0.3	-0.15	-0.14	-0.05
Free Cash Flow Per Share	0.07	0.33	0.52	-0.22	0.05	0.77		-0.15	-0.13	0.15	0.09	-0.09	0.01
Cash Per Share	0.41	0.23	0.29	-0.14	0.03	0.04	-0.15		-0.38	0.34	-0.04	-0.21	-0.38
Ev To Free Cash Flow	-0.28	-0.06	-0.23	0.44	0.38	-0.18	-0.13	-0.38		-0.79	0.07	0.97	0.98
Cash Ratio	0.57	0.31	0.02	-0.12	0.12	0.3	0.15	0.34	-0.79		-0.08	-0.77	-0.79
Cash Conversion Cycle	-0.41	0.11	0.29	-0.04	0.05	-0.15	0.09	-0.04	0.07	-0.08		0.05	0.09
Price Cash Flow Ratio	-0.22	0.02	-0.18	0.4	0.41	-0.14	-0.09	-0.21	0.97	-0.77	0.05		0.96
Cash Flow To Debt Ratio	-0.34	-0.03	-0.07	0.36	0.33	-0.05	0.01	-0.38	0.98	-0.79	0.09	0.96

Click cells to compare fundamentals

About Protalix Biotherapeutics Financial Statements

Protalix Biotherapeutics investors use historical fundamental indicators, such as Protalix Biotherapeutics' Cash, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protalix Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Cash	22.7 M	31.4 M
Cash And Short Term Investments	40.1 M	33.8 M
Cash And Equivalents	17.8 M	22.5 M
Change In Cash	-3.5 M	-3.3 M
Free Cash Flow	6.7 M	7 M
Begin Period Cash Flow	27.2 M	30.8 M
Total Cashflows From Investing Activities	4.9 M	5.1 M
Other Cashflows From Financing Activities	-23.5 M	-22.3 M
Other Non Cash Items	158.7 K	166.6 K
Total Cash From Operating Activities	7.8 M	8.2 M
Total Cash From Financing Activities	-19.3 M	-18.3 M
End Period Cash Flow	22.7 M	31.4 M
Other Cashflows From Investing Activities	95.5 K	90.7 K
Cash And Cash Equivalents Changes	960.2 K	1 M
Cash Flows Other Operating	-74.7 M	-71 M
Free Cash Flow Yield	0.06	0.07
Operating Cash Flow Per Share	0.12	0.11
Free Cash Flow Per Share	0.09	0.10
Cash Per Share	0.55	0.52
Capex To Operating Cash Flow	0.17	0.18
EV To Operating Cash Flow	12.67	13.30
EV To Free Cash Flow	14.87	15.61
Price To Operating Cash Flows Ratio	14.15	14.86
Price To Free Cash Flows Ratio	16.60	17.43
Cash Ratio	0.89	0.84
Cash Conversion Cycle	243.61	255.79
Operating Cash Flow Sales Ratio	0.19	0.18
Free Cash Flow Operating Cash Flow Ratio	0.85	0.77
Cash Flow Coverage Ratios	1.41	1.48
Price Cash Flow Ratio	14.15	14.86
Cash Flow To Debt Ratio	1.41	1.48

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

GOOG	Alphabet Inc Class C
V	Visa Class A
MSFT	Microsoft

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Protalix Cash from 2010 to 2026

Latest Protalix Biotherapeutics' Cash Growth Pattern

Protalix Cash Regression Statistics

Protalix Cash History

Other Fundumenentals of Protalix Biotherapeutics

Protalix Biotherapeutics Cash component correlations

About Protalix Biotherapeutics Financial Statements

Also Currently Popular

Additional Tools for Protalix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY